Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants

HIV Clinical Trials

Volumn 3, Issue 6, 2002, Pages 483-491

  Burbano, Ximena ^a   Miguez Burbano, Maria Jose ^a   McCollister, Kathryn ^a   Zhang, Guoyan ^a   Rodriguez, Allan ^a   Ruiz, Phillip ^a   Lecusay, Robert ^a   Shor Posner, Gail ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

HIV hospitalization; Hospitalization costs; Selenium therapy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NUCLEOSIDE DERIVATIVE; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SELENIUM;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CELL COUNT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SCREENING; DRUG USE; FEMALE; GENDER; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TIME; TOXICITY; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHEMOTHERAPY, ADJUVANT; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FLORIDA; HIV INFECTIONS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; SELENIUM; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0036865408     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/A7LC-7C9V-EWKF-2Y0H     Document Type: Article

References (29)

1. Bentham WD, Cai L, Schulman KA. Characteristics of hospitalizations of HIV-infected patients: an analysis of data from the 1994 healthcare cost and utilization project. J Acquir Immune Defic Syndr. 1999;22:503-508.
2. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:143-152.
3. Ashley EA, Johnson MA, Lipman MC. Human immunodeficiency virus and respiratory infection. Curr Opin Pulm Med. 2000;6(3):240-245.
4. Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Resp Crit Care Med. 2000;162(1):64-67.
5. Baum MK, Shor-Posner G, Lai S, et al. High risk of HIV-related mortality is associated with selenium deficiency. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 15(5):370-374.
6. Scrimshaw NS, Taylor CE, Gordon JE. Interactions of nutrition and infection. Am J Med Sci. 1959;237:367-381.
7. Wynn M, Wynn A. Reducing waiting lists for hospital admission: community nutrition services reduce the need for hospital beds. Nutr Health. 2001;15(1):3-16.
8. Tang AM, Graham NM, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. Am J Epidemiol. 1996;143(12):1244-1256.
9. Burbano X, Miguez MJ, Lecusay R, Rodriguez A, Baum M, Shor-Posner G. Thrombocytopenia in HIV-infected drug users in the HAART era. Platelets. 2001;2(8):456-461.
10. Shor-Posner G, Miguez MJ, Pineda LM, et al. Impact of selenium status on the pathogenesis of mycobacterial disease in HIV-1-infected drug users during the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29(2):169-173.
11. Rukgauer M, Klein J, Kruse-Jarres JD. Reference values for the trace elements copper, manganese, selenium, and zinc in the serum/plasma of children, adolescents, and adults. J Trace Elem Med Bio. 1997;11(2):92-98.
12. Yang G, Zhou R. Further observations on the human maximum safe dietary selenium intake in a seleniferous area of China. J Trace Elem Electr Health Dis. 1994;8:159-165.
13. American Hospital Association. Hospital Statistics. Chicago, IL: American Hospital Association Press; 1999.
14. Lavalle C, Aguilar JC, Pena F, Estrada-Aguilar JL, Avina-Zubieta JA, Madrazo M. Reduction in hospitalization costs, morbidity, disability, and mortality in patients with AIDS treated with protease inhibitors. Arch Med Res. 2000;31(5):515-519.
15. Cirelli A, Ciardi M, de Simone C, Sorice F, Giordano R, Ciaralli L, Costantini S. Serum selenium concentration and disease progress in patients with HIV infection. Clin Biochem. 1991;24(2):211-214.
16. Benton D, Cook R. Selenium supplementation improves mood in a double-blind crossover trial. Psychopharm. 1990;102(4):549-550.
17. Rayman MP. The importance of selenium to human health. Lancet. 2000;356:233-241.
18. Beck MA. Selenium and host defense towards viruses. Proc Nutr Soc. 1999;58(3):707-711.
19. Levander OA, Beck MA. Selenium and viral virulence. Brit Med Bul. 1999;55(3):528-533.
20. Kiremidjian-Schumacher L, Roy M. Selenium and immune function. Z Ernhrungswiss. 1998;37(S1):50-56.
21. Look MP, Rockstroh JK, Rao GS, et al. Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection. Eur J Clin Nutr. 1997;51(4):266-272.
22. Look MP, Rockstroh JK, Rao GS, Kreuzer KA, Spengler U, Sauerbruch T. Serum selenium versus lymphocyte subsets and markers of disease progression and inflammatory response in human immunodeficiency virus-1 infection. Bio Trace Elem Res. 1997;56(1):31-41.
23. Combs GF Jr. Selenium as a cancer preventive agent. In: Hatfield DL, ed. Selenium Its Molecular Biology and Role in Human Health. Norwell, MA: Kluwer Academic Publishers; 2001:205-218.
24. Berr C, Nicole A, Godin J, et al. Selenium and oxygen-metabolizing enzymes in elderly community residents: a pilot epidemiological study. J Amer Geriatr Soc. 1993;41(2):143-148.
25. Girodon F, Lombard M, Galan P, et al. Effect of micronutrient supplementation on infection in institutionalized elderly subjects: a controlled trial. Ann Nutr Metab. 1997;41(2):98-107.
26. Girodon F, Galan P, Monget AL, et al. Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: a randomized controlled trial. Arch Intern Med. 1999;159(7):748-754.
27. Rousseau MC, Molines C, Moreau J, Delmont J. Influence of highly active antiretroviral therapy on micronutrient profiles in HIV-infected patients. Ann Nutr Metab. 2000;44(5-6):212-216.
28. Campa A, Shor-Posner G, Indacochea F, et al. Mortality risk in selenium-deficient HIV-positive children. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20(5):508-513.
29. Constans J, Pellegrin JL, Sergeant C, et al. Serum selenium predicts outcome in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(3):392.